Heart Regeneration

By M. Laflamme, Charles E. Murry. Nature, 2011

1,123 citations recorded by the source corpus.

Heart failure plagues industrialized nations, killing more people than any other disease. It usually results from a deficiency of specialized cardiac muscle cells known as cardiomyocytes, and a robust therapy to regenerate lost myocardium could help millions of patients every year. Heart regeneration is well documented in amphibia and fish and in developing mammals. After birth, however, human heart regeneration becomes limited to very slow cardiomyocyte replacement. Several experimental strategies to remuscularize the injured heart using adult stem cells and pluripotent stem cells, cellular reprogramming and tissue engineering are in progress. Although many challenges remain, these interventions may eventually lead to better approaches to treat or prevent heart failure.

Subfields: Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/af709f14eda725fa4c9ae386dcdd164a84b51871

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Surgery

Citations in the corpus

Structural and Functional Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells (2013, background): “We reasoned that prolonged duration in culture may be required to approach the maturation normally achieved by the human heart, which develops over a gestational period of *40 weeks and continues to mature for several years after birth [1].”
Hippo pathway effector Yap promotes cardiac regeneration (2013, background): “T adult mammalian heart has limited potential for regeneration or repair (1), and thus the loss of cardiomyocytes during injury and disease results in diminished pump function and heart failure, a primary cause of human morbidity and mortality.”
Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family (2012, background): “T inability of the adult mammalian heart to regenerate after injury poses a major barrier in cardiovascular medicine (1).”
Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip (2016, positive): “The first challenge in engineering cardiac organoids and thei r on-chip forms lies in the fact that mature cardiomyocytes exhibit limited self-renewing potent ial [14].”
Pathophysiology of Myocardial Infarction (2015, positive): “Therapeutic augmentation of these very rare regenerative events is a major goal of research in the cardiovascular field (80, 210).”
Cardiomyocyte proliferation contributes to heart growth in young humans (2013, background): “Current knowledge of cardiac development would place cardiogenic stem and progenitor cells upstream of dividing cardiomyocytes, but available methods in humans cannot differentiate these two processes (3, 18, 39, 40).”
Nanotopography-guided tissue engineering and regenerative medicine (2012, background): “tacts, and synchronous, anisotropic contraction as well as anisotropic action potential propagation [168].”
Mammalian Heart Renewal by Preexisting Cardiomyocytes (2012, neutral): “Tissue autofluorescence can reduce the sensitivity and specificity of immunofluorescent methods of detecting cell cycle activity 5,13 , including as cell cycle markers or incorporation of halogenated nucleotide analogues.”